Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 770371 dose-escalation and expansion study with and without ezabenlimab in advanced solid tumors
jRCT2031220031Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
01
Overview
Phase 1, open-label trial of BI 770371 and ezabenlimab in Nonhematologic neoplasms (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of dose-limiting toxicities. Started Jul 2022; status: recruiting.
02
Drugs
BI 770371ezabenlimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031220031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220031.